RJA
SLXP

Raymond James & Associates’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Raymond James & Associates’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-10,190
Closed -$1.59M – 2376
2014
Q3 		$1.59M Buy
10,190
+93
+0.9% +$13.5K 0.01% 1212
2014
Q2 		$1.25M Buy
+10,097
New +$1.12M 0.01% 1366

Other funds holding SLXP

PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James & Associates's SLXP Position: Q4 2014 in Review

Raymond James & Associates sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q4 2014, closing a stake of 10,190 shares — an estimated $1.59M sold.

Raymond James & Associates first reported a position in SLXP in Q2 2014 and held it in 2 quarters. The position peaked at $1.59M in Q3 2014. 346 funds tracked by Wall St. Rank hold SLXP as of Q4 2014.

  • Raymond James & Associates reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q4 2014 after selling out during the quarter.
  • Raymond James & Associates sold 10,190 SALIX PHARMACEUTICALS LTD DEL shares in Q4 2014, an estimated $1.59M.
  • Raymond James & Associates first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2014 and held it in 2 quarters.
  • Raymond James & Associates's SALIX PHARMACEUTICALS LTD DEL position peaked at $1.59M in Q3 2014.
  • 346 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q4 2014.

Based on Raymond James & Associates's 13F filing for Q4 2014, filed 11 Feb 2015.